125 related articles for article (PubMed ID: 36412035)
1. [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Tanaka Y; Oota R; Takagi Y; Kodama W; Nishimura K; Hamasaki T; Fukino S; Suo K
Gan To Kagaku Ryoho; 2022 Nov; 49(11):1271-1273. PubMed ID: 36412035
[TBL] [Abstract][Full Text] [Related]
2. A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome.
Kotaka S; Yasui H; Tsubouchi H; Mori M; Kotani H; Yoshimura A; Ouchi A; Okuno M; Komori K; Shimizu Y; Suzuki S
Nagoya J Med Sci; 2023 Nov; 85(4):814-821. PubMed ID: 38155625
[TBL] [Abstract][Full Text] [Related]
3. Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
Ohsumi S; Nakamura S; Miyata H; Watanabe C; Den H; Arai M
Jpn J Clin Oncol; 2022 Nov; 52(11):1265-1269. PubMed ID: 35905458
[TBL] [Abstract][Full Text] [Related]
4. Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report.
Cheng J; Ruan X; Du J; Jin F; Li Y; Liu X; Wang H; Gu M; Mueck AO
J Ovarian Res; 2021 Dec; 14(1):176. PubMed ID: 34895280
[TBL] [Abstract][Full Text] [Related]
5. Germline BRCA2 Pathogenic Variant in Primary Breast Cancer of a Down Syndrome Individual.
Shinohara T; Asoda T; Nakano Y; Yamada H; Fujimori Y
Am J Case Rep; 2023 Dec; 24():e942208. PubMed ID: 38157332
[TBL] [Abstract][Full Text] [Related]
6. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
7. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
Speight B; Tischkowitz M
J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
[TBL] [Abstract][Full Text] [Related]
8. [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
Badora A; Kaleta B; Nowara E; Sikora-Jopek M; Budryk M; Smok-Ragankiewicz A
Ginekol Pol; 2013 Oct; 84(10):892-6. PubMed ID: 24273914
[TBL] [Abstract][Full Text] [Related]
9. [Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Tsubono M; Kaneko I; Kii E; Tanaka T; Murata T; Kamimura K; Deguchi Y; Nonogaki H; Yasumizu R
Gan To Kagaku Ryoho; 2005 Mar; 32(3):365-9. PubMed ID: 15791819
[TBL] [Abstract][Full Text] [Related]
10. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
Jacobs C; Pichert G; Harris J; Tucker K; Michie S
Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
[TBL] [Abstract][Full Text] [Related]
11. [Hereditary Breast and Ovarian Cancer(HBOC)in a Young Adult-A Case Report].
Adachi K; Kubota H; Suzuki S; Hirano T; Ishibashi N; Sakurai K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1843-1845. PubMed ID: 35046349
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
13. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
14. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
15. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
[TBL] [Abstract][Full Text] [Related]
17. [A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].
Kitagawa D; Nako Y; Honda Y; Shigekawa T; Horiguchi K; Aruga T; Yamashita T; Kuroi K
Gan To Kagaku Ryoho; 2012 Jun; 39(6):1013-6. PubMed ID: 22705705
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
20. [In Situ Ductal Carcinoma with Hereditary Breast and Ovarian Cancer Syndrome in a Patient Who Received Contralateral Risk-Reducing Mastectomy-A Case Report].
Kosaka Y; Kikuchi M; Nishimiya H; Katoh H; Kawaguchi R; Araki N; Shimazu M; Tsumura H; Waraya M; Takada F; Sengoku N; Sangai T
Gan To Kagaku Ryoho; 2020 Sep; 47(9):1387-1389. PubMed ID: 33130707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
